TAmiRNA to present miRNA biomarker advances at SSCC/SGK in Zürich

Vienna, Austria: Biotech and diagnostic innovator TAmiRNA is to make its first appearance at the Swiss Society of Clinical Chemistry (SKGC/SSCC) Annual Assembly early next month.

TAmiRNA will use the conference to highlight its its proprietary miND® NextGen small RNA-sequencing platform with an array of spike-ins that led to the development of hepatomiR® – Europe´s first CE-IVD marked test to measure microRNA biomarkers of liver function. Together, these assets demonstrate the performance of TAmiRNA´s discovery pipeline for microRNA diagnostic biomarkers.

miRNAs as novel biomarkers

TAmiRNA will be represented at the Zürich conference by its CEO and Chief Scientific Officer Dr. Matthias Hackl. He will contribute to the scientific program with his presentation ‘MicroRNAs as a novel class of biomarkers’ as part of Session 6: New Technologies on Day Three of the Conference (Friday, September 6, 0830-0945 hrs.).

“The capability to pinpoint relevant miRNA biomarkers and build elaborate markers of disease and physiology are crucial in modern medicine,” Dr. Hackl explained.

Multiomic approach

“I will also show how advanced small RNA sequencing to produce faster and more targeted results are also a key part of this picture and that TAmiRNA has been successful in using complex biological ‘big data’ to identify more rapidly novel associations between biological entities, to create a faster track bioinformatic pipeline,” he continued.

“Our recently developed hepatomiR® test is a first-in-class molecular diagnostic test to assess liver function and increase the safety of liver surgery” he added.

About TAmiRNA

TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis, and prognosis of disease, and as companion diagnostic tests to support treatment decisions. Through its CRO business, TAmiRNA enables clients from academic to private sectors to perform high-quality.

TAmiRNA is among Europe´s first companies that have CE-marked a microRNA-based test – hepatomiR® – which is intended for the diagnosis of liver function in liver cancer patients.

For its work on circulating microRNAs in bone disease, TAmiRNA is receiving funding from the European Union’s Horizon 2020 research and innovation program under the MARIE SKŁODOWSKA-CURIE grant agreement no. 860898. For TAmiRNA´s work on novel drug safety biomarkers, TAmiRNA receives funding from the Innovative Medicines Initiative 2 Joint Undertaking “TransBioLine” under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. For its work on senescence-associated biomarkers, TAmiRNA is receiving funding from Eureka-Eurostars grant Ab-SENS. For its work on novel liver function biomarkers, TAmiRNA is receiving funding from the Vienna Business Agency as well as FFG.

More information available at: www.tamirna.com

About SSCC/SGKC 2024

The Schweizerische Gesellschaft für Klinische Chemie (Swiss Society of Clinical Chemistry) is one of Europe’s most eminent life science organisations. The SSCC/SGK Annual Assembly attracts scientists and academics from all over Europe.

The SSCC/SGKC Annual Assembly 2024 is a three-day event, opening September 4, 2024, at the Technopark campus in Zürich. The 2024 theme of ‘Modern Times in Laboratory Medicine’ sets the stage for a multi-track exploration of the influence of cutting-edge technologies in the field of clinical chemistry.

The meeting is organised by the SGKC with further details at: https://www.sscc2024.ch/

Resources

Click on TAmiRNA EV characterization services to learn more.
Click on TAmiRNA miND® spike-ins for small RNA-sequencing for further information.